Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019) Preclinical evaluation of the pan-FGFR inhibitor LY2874455 in FRS2-amplified liposarcoma. Special Issue “Fibroblast Growth Factor Receptor (FGFR) Signaling Pathway in Tumor: Cells 2019, 8(2), 189; PDF (Open Access) DOI:10.3390/cells8020189 
Løvf M, Zhao S, Axcrona U, Johannesen B, Bakken AC, Carm KT, Hoff AH, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2019) Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity. Eur Urology DOI: 10.1016/j.eururo.2018.08.009
Myklebost O (Ed) Genomsekvensering for bedre persontilpasning av kreftbehandling. (100 siders rapport fra Norsk KreftGenomikkonsortium) Jan 2019 pdf
Nakken S, Saveliev V, Hofmann O, Møller P, Myklebost O, Hovig E Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for germline screening in cancer (2019) bioRxiv preprint doi:10.1101/846089
